Immuno-Oncology | Specialty

Pembrolizumab Plus Chemo Shows Promise in Urothelial Carcinoma

February 19th 2017

Combining the PD-1 inhibitor pembrolizumab with chemotherapy induced objective responses in one-third of patients with previously treated metastatic urothelial carcinoma.

Dr. Balar on Results of KEYNOTE-052 in Urothelial Cancer

February 18th 2017

Arjun Balar, MD, director, Genitourinary Medical Oncology Progam, NYU Langone Medical Center, discusses the results from the KEYNOTE-053 trial in cisplatin-ineligible advanced urothelial carcinoma.

Dr. Spratt on Combination of Immunotherapy and Radiation in Prostate Cancer

February 18th 2017

Daniel Eidelberg Spratt, MD, assistant professor, radiation oncology, University of Michigan Health System, discusses the combination of immunotherapy and radiation in patients with prostate cancer.

Dr. Wilky on Pembrolizumab Plus Axitinib in Sarcoma

February 18th 2017

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses a phase II trial exploring concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in advanced alveolar soft part sarcoma and other soft tissue sarcomas.

Dr. Herrera on Next Steps of Drug Combinations for Hodgkin Lymphoma

February 17th 2017

Alex Herrera, MD, assistant professor, Department of Hematology and Hematologic Cell Transplantation, City of Hope, discusses next steps for a phase I/II study of brentuximab vedotin (Adcetris) in combination with nivolumab (Opdivo) in patients with relapsed or refractory Hodgkin lymphoma.

Dr. Gordon on Immunotherapy Treatment for Osteosarcoma

February 17th 2017

Nancy B. Gordon, MD, assistant professor, department of pediatrics, The University of Texas MD Anderson Center, discusses immunotherapy treatments for osteosarcoma.

Dr. Apolo on Study of Cabozantinib Plus Nivolumab and Ipilimumab in Urothelial Carcinoma

February 17th 2017

Andrea B. Apolo, MD, chief of bladder cancer section, National Cancer Institute, discusses the phase I study of cabozantinib (Cabometyx) plus nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with refractory metastatic urothelial carcinoma (mUC) and other genitourinary tumors.

Immunotherapy, Molecular Testing Propel Dramatic Changes in Lung Cancer Care

February 16th 2017

2017 is poised to be another pivotal year in non–small cell lung cancer, given the exciting advances in the field at the end of last year.

Immunotherapy Needs a New Math

February 15th 2017

A group of doctors and other healthcare industry professionals have set out to develop a more efficient tool for assessing the true value of immuno-oncology drugs.

Antibiotic Use May Damper the Efficacy of Checkpoint Inhibitors

February 14th 2017

Use of antibiotics up to a month before treatment with a checkpoint inhibitor may decrease the efficacy of the immunotherapy agent, results of a retrospective analysis show.

Dr. Gangadhar on Combination Regimens for Melanoma

February 14th 2017

Tara C. Mitchell, MD, assistant professor of Medicine, Perelman School of Medicine at the Hospital of the University of Pennsylvania, discusses new combination regimens for patients with melanoma.

Dr. Postow on Immunotherapy Advancements in Melanoma

February 13th 2017

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the advancements that have recently taken place in immunotherapy in the field of melanoma.

Dr. Neal on Ongoing Trials of Immunotherapy for Lung Cancer

February 11th 2017

Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses ongoing trials in immunotherapy for patients with lung cancer.

Pharmaceutical Leaders Highlight Promise of TIGIT

February 9th 2017

John Hunter, PhD, and Maya Kotturi, PhD, answer key questions about TIGIT as a target for anticancer therapy and the current development of TIGIT-targeting drugs.

Expert Discusses PD-1 Success in MSI-H Colorectal Cancer

February 9th 2017

Michael J. Overman, MD, discusses the significance of the ongoing CheckMate-142 study and the next steps in microsatellite instability-high metastatic colorectal cancer.

Dr. Ku on Immunotherapy in Gastric and Esophageal Cancer

February 9th 2017

Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center discusses immunotherapy treatments for patients with gastric and esophageal cancers.

TIGIT Emerges as New Target for Immune Checkpoint Blockade Strategies

February 9th 2017

As researchers continue to identify a growing number of immune checkpoints as targets for anticancer therapy, the recently discovered TIGIT pathway is emerging as a promising new avenue for exploration.

Dr. Mutti on Current Role of Immunotherapy for Mesothelioma

February 9th 2017

Luciano Mutti, MD, professor of Cancer Research, University of Salford Manchester, discusses the current role of immunotherapy for patients with mesothelioma.

Less Common Side Effects With Immunotherapy in Melanoma

February 8th 2017

Immunotherapy in Melanoma: Recognizing an Endocrinopathy

February 8th 2017